Instrucciones de búsqueda:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Navegar por los elementos (12 total)
-
Autor: Boulware, David R., Matthew F. Pullen, Ananta S. Bangdiwala, Katelyn A. Pastick, Sarah M. Lofgren, Elizabeth C. Okafor, Caleb P. Skipper, Alanna A. Nascene, Melanie R. Nicol, Mahsa Abassi, Nicole W. Engen, Matthew P. Cheng, Derek LaBar, Sylvain A.…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-08-06
Descripción: This reports on a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. -
Autor: ACTT- Study Group
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2022-05-23
Descripción: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to… -
Autor: The RECOVERY Collaborative Group.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-07-17
Descripción: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. -
Autor: Zhu, Feng-Cai, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jing-Xin Li, Bei-Fang Yang, Ling Wang, Wen-Juan Wang, Shi-Po Wu, Zhao Wang, Xiao-Hong Wu, Jun-Jie Xu, Zhe Zhang, Si-Yue Jia, Bu-Sen Wang, Yi Hu, Jing-Jing Liu, Jun Zhang,…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-07-20
Descripción: This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an… -
Autor: Corri B Levine, Sami Vasistha, Caroline Croyle Persson, LuAnn R Larson, Christopher J Kratochvil, Aneesh K Mehta, Lindsay J Hicks, Abigail E Lowe, Mark G Kortepeter, Lauren M Sauer
Tema: Emergency Management
Tipo de elemento: Publicación
Fecha de actualización: 2022-05-31
Descripción: The need for well-controlled clinical trials is fundamental to advancing medicine. Care should be taken to maintain high standards in trial design and conduct even during emergency medical events such as an infectious disease outbreak. In 2020,… -
Autor: Ella, Raches, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-03-08
Descripción: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled… -
Autor: Chappell, Keith J., Francesca L. Mordant, Zheyi Li, Danushka K. Wijesundara, Paula Ellenberg, Julia A. Lackenby, Stacey T. M. Cheung, Naphak Modhiran, Michael S. Avumegah, Christina L. Henderson, Kym Hoger, Paul Griffin, Jillian Bennet, Luca Hensen,…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-19
Descripción: Given the scale of the ongoing COVID-19 pandemic, the development of vaccines based on different platforms is essential, particularly in light of emerging viral variants, the absence of information on vaccine-induced immune durability, and potential… -
Autor: Oxford COVID Vaccine Trial Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-07-20
Descripción: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of… -
Autor: Zhang, Yanjun, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, Weixiao Han, Zhen Chen, Rong Tang, Weidong Yin, Xin Chen, Yuansheng Hu, Xiaoyong Liu, Congbing Jiang, Jingxin Li, Minnan Yang, Yan Song, Xiangxi Wang, Qiang Gao, and Fengcai…
Tema: Laboratory
Tipo de elemento: Publicación
Fecha de actualización: 2020-11-17
Descripción: With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19,… -
Autor: Playford, E. G., T. Munro, S. M. Mahler, S. Elliott, M. Gerometta, K. L. Hoger, M. L. Jones, P. Griffin, K. D. Lynch, H. Carroll, D. El Saadi, M. E. Gilmour, B. Hughes, K. Hughes, E. Huang, C. de Bakker, R. Klein, M. G. Scher, I. L. Smith, L. F.…
Tema: Laboratory
Tipo de elemento: Publicación
Fecha de actualización: 2020-04
Descripción: The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in healthy adults.